32 results
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
update at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and presenting final data from the Phase 1a portion of ADPORT-601 (PORT-6 … ) at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting later this year,” said Dr. Ian Walters, Chief Executive Officer and Chairman
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
trial, presented at the Society for Immunotherapy of Cancer in November 2023, suggests PORT-2 was well tolerated when administered as a monotherapy
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
and melanoma.
Preliminary Phase 1 data from the IMP-MEL PORT-2 clinical trial, presented at the Society for Immunotherapy of Cancer in November 2023, suggests
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
in patients with NSCLC and melanoma.
Preliminary Phase 1 data from the IMP-MEL PORT-2 clinical trial, presented at the Society for Immunotherapy
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
EXHIBIT 99.1
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
PORT 2 and 6 Presented at the Society
6-K
EX-99.2
ypms20ng8zee3
28 Nov 23
Current report (foreign)
4:01pm
6-K
EX-99.1
jikknq
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
gk7wcqtk21
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.2
6zc 4m7c7fq
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.1
lzz276tembjr6u 1ye
9 Nov 22
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
4:01pm
6-K
EX-99.2
jgi 6xpp1sk
29 Aug 22
Current report (foreign)
4:00pm
6-K
EX-99.1
zoplv3fw6
1 Aug 22
Current report (foreign)
4:48pm
6-K
EX-99.2
2c9h3in
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
b04iib9n5 hrrymmofi
23 Nov 21
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.1
2ostc6j1 1zjd
30 Aug 21
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.1
9lqdm04cxr08jqyis
28 Jul 21
Current report (foreign)
9:37am
6-K
yx6uya
17 Mar 20
Report of Foreign Private Issuer
11:28am